First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment f...

詳細記述

保存先:
書誌詳細
出版年:Haematologica
主要な著者: Larocca, Alessandra, Mina, Roberto, Offidani, Massimo, Liberati, Anna Marina, Ledda, Antonio, Patriarca, Francesca, Evangelista, Andrea, Spada, Stefano, Benevolo, Giulia, Oddolo, Daniela, Innao, Vanessa, Cangiolosi, Clotilde, Bernardini, Annalisa, Musto, Pellegrino, Amico, Valeria, Fraticelli, Vincenzo, Paris, Laura, Giuliani, Nicola, Falcone, Antonietta Pia, Zambello, Renato, De Paoli, Lorenzo, Romano, Alessandra, Palumbo, Antonio, Montefusco, Vittorio, Hájek, Roman, Boccadoro, Mario, Bringhen, Sara
フォーマット: Artigo
言語:Inglês
出版事項: Ferrata Storti Foundation 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109734/
https://ncbi.nlm.nih.gov/pubmed/31248973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.220657
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料